• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Hong Kong·Healthcare·8143.HK
Share

Good Fellow Healthcare Holdings Limited Stocks

HK$ 0.08Last Updated 11.06.2026

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

HK$ 10.79M

HK$ 0.08
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Good Fellow Healthcare Holdings Limited, an investment holding entity based in Central, Hong Kong, offers a range of general hospital services both within the People's Republic of China and globally. These services feature medical and surgical inpatient care, alongside health check-ups and diagnostic examinations. As of March 31, 2022, the company oversaw two general hospitals, situated in Putain and Beijing. Furthermore, it engages in medical investment, hospital administration, and consulting management services. Established in 2001, the company rebranded to its current name in February 2019, having previously operated as Hua Xia Healthcare Holdings Limited. It functions as a subsidiary of Solar Star Global Limited.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overvalued on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.06.2026 02:48

US and Iran reach peace deal - Trump

14.06.2026 21:00

SpaceX debuts, OpenAI is one step closer to the stock exchange: highlights of the IPO by June 14

14.06.2026 18:01

ECB has raised rates, next move is for the Fed: what will be Kevin Warsh's first decision

14.06.2026 15:01

"A premium for candor": how top executives' comments affect companies' share prices

13.06.2026 22:31

U.S. and Iran to sign agreement on June 14, Strait of Hormuz to reopen - Trump

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026